Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

NCT01849263 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

NIH

Sponsor class

Conditions

Grade 3a Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)